论文部分内容阅读
目的利用硝酸甘油诱导的偏头痛模型,检测瞬时感受器电位香草酸亚1(TRPV1)的表达,探讨TRPV1受体是否参与硝酸甘油诱导的偏头痛过程。方法成年雌性Wistar大鼠24只,按随机数字法分为硝酸甘油模型组和对照组。模型组大鼠颈部皮下注射硝酸甘油(10mg/kg),对照组在相同部位注射等量生理盐水。观察大鼠行为表现,分别于注射药物1h、2h、4h和8h取大鼠双侧的三叉神经节及硬脑膜,采用RT-PCR、Western Blot及间接免疫荧光法检测TRPV1受体表达。结果对照组各时间点三叉神经节均可见TRPV1受体表达,但各时间点相对表达无显著差异(P>0.05);模型组三叉神经节TRPV1受体1h、2h mRNA和蛋白相对表达量与对照组比较下调,而4h、8h表达升高(P<0.05);模型组三叉神经节TRPV1受体8h表面蛋白相对表达量高于对照组(P<0.05);间接免疫荧光显示模型组硬脑膜8h TRPV1受体表达高于对照组。结论 TRPV1受体在硝酸甘油诱导的偏头痛模型中表达变化,提示抑制或拮抗TRPV1受体将是治疗偏头痛的新思路。
Objective To detect the transient receptor potential vanilloid sub 1 (TRPV1) expression by nitroglycerin-induced migraine model and to explore whether TRPV1 receptor participates in the migraine process induced by nitroglycerin. Methods Twenty-four adult female Wistar rats were randomly divided into nitroglycerin model group and control group. The rats in the model group were subcutaneously injected nitroglycerin (10 mg / kg) into the neck, while the control group were injected with the same amount of saline at the same place. The behavior of rats was observed. The bilateral trigeminal ganglion and dura mater was taken at 1h, 2h, 4h and 8h after injection respectively. The expression of TRPV1 receptor was detected by RT-PCR, Western Blot and indirect immunofluorescence. Results The expression of TRPV1 receptor in the trigeminal ganglion was observed in the control group at each time point, but there was no significant difference at each time point (P> 0.05). The mRNA and protein expressions of TRPV1 receptor in the trigeminal ganglion at 1, (P <0.05). The relative expression of TRPV1 receptor 8h surface protein in the model group was higher than that in the control group (P <0.05). Indirect immunofluorescence showed that the expression of TRPV1 receptor in the model group was significantly higher than that in the control group TRPV1 receptor expression higher than the control group. Conclusion The expression of TRPV1 receptor in the model of migraine induced by nitroglycerin suggests that the inhibition or antagonism of TRPV1 receptor will be a new way to treat migraine.